Journal: Cancer Discovery

Abbreviation

Cancer Discov

Publisher

American Association for Cancer Research

Journal Volumes

ISSN

2159-8274
2159-8290

Description

Filters

2012 - 201922020 - 20255
Reset filters

Search Results

Publications 1 - 7 of 7
  • A Molecular Voyage: Multi-Omics Insights into Circulating Tumor Cells
    Item type: Review Article
    Zhang, Yu Wei; Gvozdenovic, Ana; Aceto, Nicola (2024)
    Cancer Discovery
    Circulating tumor cells (CTCs) play a pivotal role in metastasis, the leading cause of cancer-associated death. Recent improvements of CTC isolation tools, coupled with a steady development of multiomics technologies at single-cell resolution, have enabled an extensive exploration of CTC biology, unlocking insights into their molecular profiles. A detailed molecular portrait requires CTC interrogation across various levels encompassing genomic, epigenetic, transcriptomic, proteomic and metabolic features. Here, we review how state-of-the-art multiomics applied to CTCs are shedding light on how cancer spreads. Further, we highlight the potential implications of CTC profiling for clinical applications aimed at enhancing cancer diagnosis and treatment.Significance: Exploring the complexity of cancer progression through cutting-edge multiomics studies holds the promise of uncovering novel aspects of cancer biology and identifying therapeutic vulnerabilities to suppress metastasis.
  • Cancer Research in the Age of Spatial Omics: Lessons from IMAXT
    Item type: Journal Article
    IMAXT Cancer Grand Challenges Consortium; Bressan, Dario; Walton, Nicholas; et al. (2025)
    Cancer Discovery
    The Imaging and Molecular Annotation of Xenografts and Tumors Cancer Grand Challenges team was set up with the objective of developing the “next generation” of pathology and cancer research by using a combination of single-cell and spatial omics tools to produce 3D molecularly annotated maps of tumors. Its activities overlapped, and in some cases catalyzed, a spatial revolution in biology that saw new technologies being deployed to investigate the roles of tumor heterogeneity and of the tumor micro-environment.
  • EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC
    Item type: Journal Article
    Krishnamoorthy, Gnana P.; Davidson, Natalie R.; Leach, Steven D.; et al. (2019)
    Cancer Discovery
  • Highly Multiplexed Tissue Imaging in Precision Oncology and Translational Cancer Research
    Item type: Review Article
    Bollhagen, Alina; Bodenmiller, Bernd (2024)
    Cancer Discovery
    Precision oncology tailors treatment strategies to a patient's molecular and health data. Despite the essential clinical value of current diagnostic methods, hematoxylin and eosin morphology, immunohistochemistry, and gene panel sequencing offer an incomplete characterization. In contrast, highly multiplexed tissue imaging allows spatial analysis of dozens of markers at single-cell resolution enabling analysis of complex tumor ecosystems; thereby it has the potential to advance our understanding of cancer biology and supports drug development, biomarker discovery, and patient stratification. We describe available highly multiplexed imaging modalities, discuss their advantages and disadvantages for clinical use, and potential paths to implement these into clinical practice. Significance: This review provides guidance on how high-resolution, multiplexed tissue imaging of patient samples can be integrated into clinical workflows. It systematically compares existing and emerging technologies and outlines potential applications in the field of precision oncology, thereby bridging the ever-evolving landscape of cancer research with practical implementation possibilities of highly multiplexed tissue imaging into routine clinical practice.
  • Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
    Item type: Journal Article
    Kornauth, Christoph; Pemovska, Tea; Vladimer, Gregory I.; et al. (2022)
    Cancer Discovery
    Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient’s tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of patients with cancer. A promising method may be drug profiling of patient biopsy specimens with single-cell resolution to directly quantify drug effects. We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to guide treatments in 143 patients with advanced aggressive hematologic cancers. Fifty-six patients (39%) were treated according to scFPM results. At a median follow-up of 23.9 months, 30 patients (54%) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared with their previous therapy. Twelve patients (40% of responders) experienced exceptional responses lasting three times longer than expected for their respective disease. We conclude that therapy matching by scFPM is clinically feasible and effective in advanced aggressive hematologic cancers. SIGNIFICANCE: This is the first precision medicine trial using a functional assay to instruct n-of-one therapies in oncology. It illustrates that for patients lacking standard therapies, high-content assaybased scFPM can have a significant value in clinical therapy guidance based on functional dependencies of each patient’s cancer.
  • Functional Metabolic Screen Identifies 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 as an Important Regulator of Prostate Cancer Cell Survival
    Item type: Journal Article
    Ros, Susana; Santos, Claudio R.; Moco, Sofia; et al. (2012)
    Cancer Discovery
  • Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
    Item type: Journal Article
    Azorín, Daniel D.; Hoffmann, Dirk C.; Hebach, Nils R.; et al. (2025)
    Cancer Discovery
    Glioblastomas are incurable primary brain tumors that depend on neural-like cellular processes, tumor microtubes (TM), to invade the brain. TMs also interconnect single tumor cells to a communicating multicellular network that resists current therapies. In this study, we developed a combined, comprehensive in vitro/in vivo anti-TM drug screening approach, including machine learning–based analysis tools. Two protein kinase C (PKC) modulators robustly inhibited TM formation and pacemaker tumor cell–driven, TM-mediated glioblastoma cell network communication. As TM-unconnected tumor cells exhibited increased sensitivity to cytotoxic therapy, the PKC activator TPPB was combined with radiotherapy, and long-term intravital two-photon microscopy paired with spatially resolved multiomics revealed anti-TM and antitumor effects. TPPB treatment also decreased the expression of tweety family member 1 (TTYH1), a key driver of invasive TMs. Our study establishes a novel screening pipeline for anti-TM drug development, identifies a TM master regulator pathway, and supports the approach of TM targeting for efficient brain tumor therapies.
Publications 1 - 7 of 7